GlassScriptPhysician profile
Lawrence S Feigenbaum
NPI 1851633242
$36,984.39
in general payments reported to CMS, 2019-2025
41 companies · $2,346 in 2025
The $2,346 reported for 2025 was more than what 80% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,279 · 2020: $8,539 · 2021: $11K · 2022: $6,191 · 2023: $4,454 · 2024: $2,757 · 2025: $2,346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,922 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,250 · Education: $385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,922.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,250.00 |
| Education | $384.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $23,556.97 | 2019-2025 | Otezla, Otezla |
| Abbvie INC. | $2,828.46 | 2019-2025 | |
| Janssen Biotech, INC. | $2,444.70 | 2019-2025 | Tremfya, Remicade, Simponi |
| Sun Pharmaceutical Industries INC. | $1,159.82 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Lilly USA, LLC | $1,052.70 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $846.46 | 2019-2025 | |
| Pfizer INC. | $592.37 | 2019-2025 | |
| Dermavant Sciences, INC. | $501.82 | 2022-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $497.35 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $463.53 | 2021-2025 | |
| Ucb, INC. | $410.70 | 2019-2025 | Bimzelx, Cimzia |
| Incyte Corporation | $354.79 | 2021-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $269.72 | 2019-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $239.28 | 2020-2025 | Aklief, Oracea, Epsolay |
| Leo Pharma INC. | $209.64 | 2019-2025 | Adbry, Anzupgo |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Feigenbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.